Chattem buying Gold Bond anti-itch line from Martin Himmel.
This article was originally published in The Tan Sheet
Executive Summary
CHATTEM TO PURCHASE GOLD BOND LINE FROM MARTIN HIMMEL, the Chattanooga, Tenn.-based health and beauty aids manufacturer announced on April 10. The purchase agreement will give Chattem worldwide rights to the line of medicated powders and anti-itch creams.
You may also be interested in...
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
Chattem Acquires “Great Brands” In Wake Of J&J’s Pfizer Purchase
Chattem said its past experience with brands such as Icy Hot and Selsun Blue will make for an easier transition of its newest package acquisition